A PD-1 agonist dampened RA inflammation — but its development has stopped

Design

Post-hoc pharmacokinetic and biomarker analysis of a phase 2a double-blind randomised trial

Population

98 adults with moderate-to-severe rheumatoid arthritis

Primary outcome

Receptor occupancy and cellular/proteomic biomarker change to week 14

Effect

PD-1-high CD4 T cells down 52–57%; neutrophils reduced; IL-6-pathway signalling down-modulated

Most rheumatoid arthritis biologics block inflammatory signals; peresolimab took the opposite approach, stimulating the inhibitory checkpoint PD-1 to restrain autoreactive T cells, and had beaten placebo on disease activity in a phase 2a trial. This post-hoc analysis reports the mechanism.

At doses giving over 90% receptor occupancy, peresolimab cut PD-1-high CD4 T cells by about half, reduced neutrophils, and down-modulated inflammatory pathways including IL-6 signalling, without disturbing other immune cell types. It is an elegant demonstration that agonising a checkpoint, rather than blocking a cytokine, can quieten rheumatoid inflammation.

The honest footnote is that the drug is not coming: after a subsequent phase 2b dose-ranging study, development of peresolimab was discontinued. So this is a mechanistic lesson about PD-1 agonism as a strategy in autoimmunity, not a therapy to anticipate — worth knowing for where the field may go, not for the clinic.

• Peresolimab achieved over 90% PD-1 receptor occupancy and cut PD-1-high CD4 T cells by about 52–57%.
• Neutrophils fell and IL-6-pathway inflammatory signalling was down-modulated versus placebo.
• Other major immune cell subsets were largely unchanged, suggesting a targeted effect.
• Note the mechanism, but not as a future drug — peresolimab development has been discontinued.

Why it matters

It shows checkpoint agonism is a viable way to damp autoimmunity, informing the next generation of agents even though this one failed commercially.

Don't overread it

Post-hoc biomarker analysis of a phase 2a trial of a discontinued drug — it establishes mechanism, not clinical benefit or a coming therapy.

The statistics, in plain English

Receptor occupancy over 90% means the drug hit its target thoroughly, and the halving of PD-1-high T cells shows a real biological effect. None of this changes practice because the programme stopped — it is included for the mechanism, not the molecule.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.